Project description
Development of therapy for chronic obstructive pulmonary disease
The mission of PaloBiofarma from Spain is to discover and develop new drugs that modulate adenosine receptors. The company’s PBF-680 compound is a first-in-class oral modifying therapy for respiratory diseases, primarily chronic obstructive pulmonary disease (COPD) that urgently needs approved treatment to target disease progression. The PBF-680 specifically antagonises the adenosine 1 receptor and was found safe and well-tolerated in phase 1 trials. The compound has shown a reduction in pulmonary symptoms and inflammation in cases of mild-to-moderate asthma in phase 2 trials. The EIC-funded RESPIRE project’s goal is to demonstrate efficacy in the COPD phase 2 trial.
Objective
Palobiofarma is a Spanish biotech company with the ambition to develop new treatments for cancer and autoimmune diseases based on adenosine receptor modulation. Our compound PBF-680 is a first-in-class therapy with disease modifying effects in respiratory diseases like COPD. Over 65M
patients suffer from COPD, yet there are no approved therapies that target disease progression. PBF-680 is a unique molecule designed to specifically antagonise the Adenosine 1 Receptor (A1R). it has shown to be safe and well-tolerated in phase 1 trials and demonstrated to reduce pulmonary
symptoms and inflammation in mild-to-moderate asthmatics in phase 2 trials. With funding from the EIC Accelerator, we will demonstrate efficacy in a phase 2 trial in COPD, a market with high unmet medical need. Proven clinical efficacy will be the major milestone to raise €30M (incl €15M EIC
Equity) for a phase 3 trial, followed by an additional fund raising or IPO to independently reach market launch with PBF-680.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicineimmunologyautoimmune diseases
- medical and health scienceshealth sciencesinfectious diseasesRNA virusescoronaviruses
- medical and health sciencesclinical medicineoncology
You need to log in or register to use this function
Keywords
Programme(s)
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
31110 NOAIN
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.